Du är här

2015-09-29

Novavax, Inc.: Novavax Announces Grant of Up to $89 Million to Support Development of RSV F Vaccine to Protect Infants Via Maternal Immunization

Bill&Melinda Gates Foundation to Support Development of the RSV F Vaccine ProgramGAITHERSBURG, Md., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc.,
(Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery,
development and commercialization of recombinant nanoparticle vaccines and
adjuvants, today announced it has been awarded a grant of up to $89 million
from the Bill&Melinda Gates Foundation to support development of the RSV F
Vaccine Phase 3 clinical trial in pregnant women, planned to initiate during
the first quarter of 2016. This grant will also support regulatory licensing
efforts, providing a path to WHO prequalification. Upon licensure, Novavax
has agreed to make the RSV F Vaccine affordable and accessible to people in
the developing world.

"Respiratory syncytial virus (RSV) is the leading cause of pneumonia in
infants, and currently there are no affordable approaches to protecting
children in the developing world from this viral disease," said Dr. Keith
Klugman, Director of the Bill&Melinda Gates Foundation's Pneumonia Program.
"Maternal immunization may provide protective antibodies to infants during
the first few months of life, and we hope this vaccine will protect infants
from this disease to help them live healthy, productive lives."

"Along with today's announcement of top-line data from the Phase 2 clinical
trial of our RSV F Vaccine with the goal to protect infants via maternal
immunization, we are very gratified to receive the support of the
Bill&Melinda Gates Foundation to improve the health of infants throughout the
world," said Stanley C. Erck, President and CEO. "Our groundbreaking Phase 2
results in both maternal and older adult target populations, underscore the
promise of our RSV F Vaccine programs. We look forward to carrying our recent
momentum into the fourth quarter as we prepare to initiate two pivotal Phase
3 trials of our RSV F Vaccine."

A fact sheet on maternal immunization is available at the Novavax
website,http://novavax.com/download/files/pipeline/151_Novavax_FactSheet_FIN_D_9...

About RSV
Respiratory syncytial virus (RSV) is the most common cause of lower
respiratory tract infections and the leading viral cause of severe lower
respiratory tract disease in infants and young children worldwide, with
estimated annual infection and mortality rates of 64 million and 160,000,
respectively1. In the US, RSV is the leading cause of hospitalization of
infants2. Despite the induction of post-infection immunity, repeat infection
and lifelong susceptibility to RSV is common3,4. Currently, there is no
approved RSV vaccine available. Palivizumab is a monoclonal antibody,
licensed and sold by MedImmune as Synagis®, that targets the RSV F protein
and is used for prophylaxis against RSV disease in high risk infants.

About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to
delivering novel products to prevent a broad range of infectious diseases.
Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the
foundation for groundbreaking innovation that improves global health through
safe and effective vaccines. Additional information about Novavax is
available on the company's website, novavax.com.

References:

1 Nair, H. et al. Global burden of acute lower respiratory infections due to
respiratory syncytial virus in young children: a systematic review and
meta-analysis. Lancet , 2010; 375: 1545-1555.
2 Hall, C.B. et al. Respiratory Syncytial Virus-Associated hospitalizations
Among Children Less Than 24 Months of Age.Pediatrics , 2013; 132(2):
E341-348.
3 Glezen, W.P. et al. Risk of primary infection and reinfection with
respiratory syncytial virus. Am J Dis Child , 1986; 140:543-546.
4 Glenn GM, et al. Modeling maternal fetal RSV F vaccine induced antibody
transfer in guinea pigs. Vaccine, 2015; In
press.http://dx.doi.org/10.1016/j.vaccine.2015.08.039.

Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

ir@novavax.com
240-268-2000

Russo Partners, LLC

David Schull
Todd Davenport, Ph.D.

david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com212-845-4271

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

HUG#1954971

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.